Organon & Co Total Liabilities
Organon & Co total liabilities. Based on the latest financial reports, Organon & Co (OGN) has total liabilities worth $12.17 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OGN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Organon & Co (2018–2025)
Total liabilities of Organon & Co from 2018 to 2025. This chart illustrates how Organon & Co's total liabilities have evolved over time, based on quarterly financial data.
Organon & Co Competitors by Total Liabilities
The table below lists competitors of Organon & Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ROCKWOOL International A/S
CO:ROCK-B
|
Denmark | Dkr900.29 Million |
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NYSE:AMRX
|
USA | $2.78 Billion |
|
Aecc Aero Engine Control Co Ltd
SHE:000738
|
China | CN¥2.98 Billion |
|
Heilongjiang Agriculture Co Ltd
SHG:600598
|
China | CN¥6.97 Billion |
|
Holmen AB (publ)
ST:HOLM-B
|
Sweden | Skr25.46 Billion |
|
Post Holdings Inc
NYSE:POST
|
USA | $9.76 Billion |
|
RUBIS
F:BYN
|
Germany | €3.71 Billion |
|
Tsingtao Brewery Company Limited
F:TSI
|
Germany | €23.26 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Organon & Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OGN current and non-current assets.
Liquidity & Leverage Metrics
Organon & Co Total Liabilities Ratios Explained
Organon & Co total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 12.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Organon & Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Organon & Co (2018–2025)
The table below shows the annual total liabilities of Organon & Co from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.12 Billion | -4.07% |
| 2024-12-31 | $12.63 Billion | +4.13% |
| 2023-12-31 | $12.13 Billion | +2.37% |
| 2022-12-31 | $11.85 Billion | -2.81% |
| 2021-12-31 | $12.19 Billion | +163.66% |
| 2020-12-31 | $4.62 Billion | +31.60% |
| 2019-12-31 | $3.51 Billion | -15.27% |
| 2018-12-31 | $4.15 Billion | -- |
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive… Read more